Friday, May 20, 2022



AstraZeneca’s anti-diabetic drug gets nod for kidney disease in India

Bengaluru, Feb 8, 2021-
Pharmaceutical company AstraZeneca India on Monday announced that it has received marketing authorisation for its anti-diabetic drug — dapagliflozin — in India for the treatment of patients of chronic kidney disease (CKD) up to third stage.

This permission paves the way for the launch of Dapagliflozin Tablets 10mg into a new disease area in India.

AstraZeneca’s dapagliflozin is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with CKD, the company said in a statement.

“With the approval of dapagliflozin for CKD in India, an already effective Type-2 Diabetes and select heart failure treatment can now be used by nephrologists in the management of CKD,” said Anil Kukreja, Vice President – Medical Affairs & Regulatory, AstraZeneca India.

“Dapagliflozin is the first SGLT2 inhibitor to demonstrate such unprecedented efficacy in management of Chronic Kidney Disease,” Kukreja added.

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s dapagliflozin on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 per cent compared to placebo in patients with CKD Stages 2-4 and elevated urinary albumin excretion.

The results were consistent in patients both with and without Type-2 diabetes.

CKD is a serious, progressive condition defined by decreased kidney function affecting nearly 700 million people worldwide, many of them still undiagnosed, and the most common causes are diabetes, hypertension and glomerulonephritis. (Agency)

- Advertisement -

Yes Punjab - TOP STORIES

Punjab News

Sikh News

Transfers, Postings, Promotions

- Advertisement -spot_img

Stay Connected






Fault lines widening amongst Indian Muslim religious leaders – by Asad Mirza

New Delhi, May 16, 2022- Recent outreach activities by Muslim leaders across India relays very disturbing and hopeless signs, instead of formulating a strategy...

Growing heat, vanishing wheat, shrinking size – by Narvijay Yadav

When I bought a packet of sandwich bread in the morning, the vendor said that the ‘price has increased’. Then I saw news in...

India plays the field as a swing state. But for how long? – by Yashwant Raj

Washington, May 15, 2022- As the war in Ukraine intensified, the number of foreign political leaders descending on New Delhi shot up - current...


Health & Fitness

Intermittent fasting may slow ageing, fight cancer and diabetes: Study

New York, May 16, 2022- While people tend to follow new diets to get fit and reduce their weight, research has shown that in addition to weight loss, people who indulge in intermittent fasting may also have benefits like slow ageing, and be capable of fighting cancer as well as diabetes. Intermittent fasting diets fall generally into two categories: daily...

Gadgets & Tech